Aggregated price index
Aggregated price index with volume information
- Genetic Testing Firms stocks up 0.7% on average while median return up -0.7% in a day
- Genetic Testing Firms stocks up 2.2% on average while median return up 3.5% in a week
- Genetic Testing Firms stocks up 2.0% on average while median return up 1.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index is based on equal weighted constituencies returns,Aggregated volume information is based on sum of all constituencies volumes
- 1M winners are : Winners for past month are $MYGN 27.5%, $NTRA 22.8%, $OCX 11.6%, $FLGT 6.3%, $NEOG 2.5%
- 1M losers are : Losers for past month are $LH -2.7%, $GENE -5.2%, $CODX -13.5%, $CGIX -39.7%
- 1W winners are : Winners for past week are $MYGN 9.2%, $CODX 6.1%, $CGIX 4.9%, $GENE 4.7%, $NTRA 4.6%
- 1W losers are : Losers for past week are $OCX -1.1%, $LH -1.3%, $FLGT -15.9%
Index correlation analysis
Correlation for the past month is 19.6%, for the past 3 months is 15.2%
In the past month for a 5 days rolling window, the highest corrrelation is 53.9%, the lowest correlation is -5.8%, the latest correlation is -3.6%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 88.4% between DGX and LH
The lowest correlation is -47.7% between CODX and MYGN
What happened Shares of Co-Diagnostics (NASDAQ: CODX) were jumping 17.4% as of 3:09 p.m. EST on Wednesday. The gain came after the company announced that its joint venture, CoSara Diagnostics, received clearance in India to market the Saragene COVID-19 diagnostic test.
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its Saragene™ COVID-19 2-gene multiplex RT-PCR test as an in vitro diagnostic ("IVD")...
Fulgent Genetics, Inc. (NASDAQ:FLGT) shareholders will have a reason to smile today, with the analysts making...
TEMPLE CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis virtually participated in a pre-recorded fireside chat that will be published as part of the Piper Sandler 32...
New York City, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The global upsurge in COVID-19 has kept testing and Co-Diagnostics (NASDAQ: CODX) under the analysts’ microscope. Within its client circular, the analyst from H.C. Wainwright & Co. predicted that Co-Diagnostics' Logix Smart ABC (Influenza A/Influenza B/COVID-19) and Logix Smart SARS-CoV-2 (genes RdRp/E) multiplex tests, which it considers both highly accurate and affordable, could drive future domestic and international sales. This followed the ...
Quest Diagnostics saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 93 the day before.
MELBOURNE, Australia, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”) is pleased to announce an interview with its interim-CEO, Dr. Jerzy Muchnicki aired on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International. In the exclusive interview, Dr. Muchnicki discusses the Company’s innovative d...
TEMPLE CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it has updated its revenue guidance for the full year 2020 due to accelerating demand for its COVID-19 testing solutions. The company now expects to generate at least $300 million in revenue for the full year 2020, an increase of 28% compare...
NEOGEN (NEOG) aims to better serve the biomedical research community with a comprehensive and affordable solution for the genetic background testing of their mouse models via the partnership.